By continuing on our website, you agree to our use of the cookie for statistical and personalization purpose.
Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
Jun 05, 2020
Source: 2016 Commonwealth Fund International Health Policy Survey.
Base: Needed elective surgery in past two years.